You are here: Home: LCU 2 | 2006 : Case 5: Select publications

SELECT PUBLICATIONS

Gridelli C et al. Single-agent pemetrexed or sequentially administered pemetrexed/ gemcitabine as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy: Preliminary results of a phase II randomized trial. Proc ASCO 2005;Abstract 7156.

Jackman DM et al. Phase II study of the EGFR tyrosine kinase erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. Proc ASCO 2005;Abstract 7148.

Le Caer H et al. A multicenter phase II study of docetaxel (D) or docetaxel/gemcitabine (G) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts). (GFPC 0202). Proc ASCO 2005;Abstract 7150.

Mainwaring MG et al. Weekly docetaxel versus weekly docetaxel/gemcitabine as firstline therapy for patients who are elderly or with poor performance status (PS) or with serious comorbidities with advanced non-small cell lung cancer (NSCLC): Interim safety analysis of a Minnie Pearl Cancer Research Network phase III trial. Proc ASCO 2005;Abstract 7151.

Table of Contents

Top of Page